All blog posts
Total 23 results for
Showing 23 out of 23 results
09 2월 2023
Competition law developments in the pharma sector – 2022 round-up and what to expect in 2023
23 11월 2022
SANCTION IMPOSED BY THE SPANISH COMPETITION AUTHORITY ON A PHARMA COMPANY FOR MISUSING LITIGATION STRATEGIES REGARDING PATENTS
11 10월 2022
Update on the Teva Copaxone EU case. The EU Commission issues a Statement of Objections against Teva over alleged anti-competitive conduct consisting of misuse of divisional patents and a disparagement campaign against its closest competitor
09 2월 2022
Competition law in the pharma sector – Developments and what’s to come in 2022
29 3월 2021
CJEU CONFIRMS PAY-FOR-DELAY APPROACH AND UPHOLDS DECISION IN LUNDBECK CASES
04 3월 2021
First time EU Commission pursues case relating to divisional patent filing and litigation strategies
16 2월 2021
Excessive pricing: EU Commission accepts Aspen’s drug pricing commitments
27 11월 2020
The European Commission fines Cephalon and Teva €60.5 million in its fourth “pay-for-delay” decision
27 10월 2020
Pharmaceutical sector under increased antitrust scrutiny in the UK
05 6월 2020
Advocate General Kokott's Opinion in Lundbeck v Commission
09 4월 2020
EU Commission publishes guidance on cooperation arrangements aimed at addressing shortages during the COVID-19 crisis
Showing 23 out of 23 results
Key contacts
Kyriakos Fountoukakos
Managing Partner, Competition Regulation and Trade, Brussels
Veronica Roberts
Partner, UK Regional Head of Practice, Competition, Regulation and Trade, London
Linda Evans
Regional Head of Practice – Competition, Regulation and Trade, Australia, Sydney
